Cargando…

Associations of Fatty Liver Disease with Hypertension, Diabetes, and Dyslipidemia: Comparison between Alcoholic and Nonalcoholic Steatohepatitis

Alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH) are representative types of fatty liver disease (FLD) and have similar histologic features. In this study, we aimed to compare the associations of the two FLD types with hypertension (HT), diabetes mellitus (DM), and dyslipidemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toshikuni, Nobuyuki, Tsuchishima, Mutsumi, Fukumura, Atsushi, Arisawa, Tomiyasu, Tsutsumi, Mikihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585648/ https://www.ncbi.nlm.nih.gov/pubmed/28912806 http://dx.doi.org/10.1155/2017/9127847

Ejemplares similares

Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia
por: Toshikuni, Nobuyuki, et al.
Publicado: (2013)

Acetaldehyde-Derived Advanced Glycation End-Products Promote Alcoholic Liver Disease
por: Hayashi, Nobuhiko, et al.
Publicado: (2013)

Serum Osteopontin Predicts Degree of Hepatic Fibrosis and Serves as a Biomarker in Patients with Hepatitis C Virus Infection
por: Matsue, Yasuhiro, et al.
Publicado: (2015)

The combination of fatty liver and increased gamma-glutamyl transpeptidase levels as a risk factor for atherosclerotic plaque development in apparently healthy people
por: KINOSHITA, Kaori, et al.
Publicado: (2019)

Fractionation of gamma-glutamyltransferase in patients with nonalcoholic fatty liver disease and alcoholic liver disease
por: Sueyoshi, Shigeo, et al.
Publicado: (2016)

An Image Fusion System for Estimating the Therapeutic Effects of Radiofrequency Ablation on Hepatocellular Carcinoma
por: Toshikuni, Nobuyuki, et al.
Publicado: (2017)

Serum Endocan as a Novel Prognostic Biomarker in Patients with Hepatocellular Carcinoma
por: Ozaki, Kazuaki, et al.
Publicado: (2014)

MMP‐13 deletion decreases profibrogenic molecules and attenuates N‐nitrosodimethylamine‐induced liver injury and fibrosis in mice
por: George, Joseph, et al.
Publicado: (2017)

Alteration of Trace Elements during Pathogenesis of N-Nitrosodimethylamine Induced Hepatic Fibrosis
por: George, Joseph, et al.
Publicado: (2019)

Molecular mechanisms in the pathogenesis of N-nitrosodimethylamine induced hepatic fibrosis
por: George, Joseph, et al.
Publicado: (2019)

Advanced ultrasonography technologies to assess the effects of radiofrequency ablation on hepatocellular carcinoma
por: Toshikuni, Nobuyuki, et al.
Publicado: (2013)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Survival rates of early-stage HCV-related liver cirrhosis patients without hepatocellular carcinoma are decreased by alcohol
por: Yamada, Masayoshi, et al.
Publicado: (2011)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis
por: Chackelevicius, Carla Melisa, et al.
Publicado: (2016)

Influence of IL17A polymorphisms on the aberrant methylation of DAPK and CDH1 in non-cancerous gastric mucosa
por: Arisawa, Tomiyasu, et al.
Publicado: (2012)

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis
por: Dongiovanni, Paola, et al.
Publicado: (2015)

Murine Models of Nonalcoholic Fatty Liver Disease and Steatohepatitis
por: Ninomiya, Masashi, et al.
Publicado: (2012)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
por: Tokushige, Katsutoshi, et al.
Publicado: (2021)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Establishment and Comparison of Juvenile Female Mouse Models of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Zhou, Lishan, et al.
Publicado: (2018)

Nonalcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Childhood: Endocrine-Metabolic “Mal-Programming”
por: Manti, Sara, et al.
Publicado: (2014)

Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease
por: Lee, Hye Won, et al.
Publicado: (2016)

Gut microbiota profile in patients with nonalcoholic fatty liver disease and presumed nonalcoholic steatohepatitis
por: Mohammadi, Zahra, et al.
Publicado: (2022)

Can Nutritional Supplements Benefit Patients With Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease?
por: Baradeiya, Ahmed M, et al.
Publicado: (2023)

Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Baek, Jung-Hwan, et al.
Publicado: (2023)

Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease
por: Kim, Young Seok, et al.
Publicado: (2013)

Hepatoprotective Effect of Kombucha Tea in Rodent Model of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Lee, Chanbin, et al.
Publicado: (2019)

Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Lee, Chanbin, et al.
Publicado: (2019)

Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma
por: Cernea, Simona, et al.
Publicado: (2023)

Characterization of gut microbiome composition in Iranian patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Abdollahiyan, Sara, et al.
Publicado: (2023)

Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease
por: Akhtar, Daud H., et al.
Publicado: (2019)

Periodontal disease–related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral‐liver axis
por: Kuraji, Ryutaro, et al.
Publicado: (2021)

Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years
por: Kawanaka, Miwa, et al.
Publicado: (2020)

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)
por: Murphy, William A., et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research
por: Berardo, Clarissa, et al.
Publicado: (2020)

Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Kim, Gyuri, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cdvtaijjlqtpbme6g08gcofhb2